HOME >> BIOLOGY >> NEWS
Pairing nanoparticles with proteins

UPTON, NY -- In groundbreaking research, scientists have demonstrated the ability to strategically attach gold nanoparticles -- particles on the order of billionths of a meter -- to proteins so as to form sheets of protein-gold arrays. The nanoparticles and methods to create nanoparticle-protein complexes can be used to help decipher protein structures, to identify functional parts of proteins, and to "glue" together new protein complexes. Applications envisioned by the researchers include catalysts for converting biomass to energy and precision "vehicles" for targeted drug delivery.

The research, which was conducted at the U.S. Department of Energy's Brookhaven National Laboratory, will be published in the July 2, 2007 issue of the journal Angewandte Chemie.

"Our study demonstrates that nanoparticles are appealing templates for assembling functional biomolecules with extensive potential impact across the fields of energy conversion, structural biology, drug delivery, and medical imaging," said lead author Minghui Hu, a postdoctoral student working with James Hainfeld, Raymond Brinas, Luping Qian, and Elena Lymar in the Biology Department at Brookhaven Lab.

In the field of energy conversion, scientists have been searching for efficient ways to convert organic fuels such as ethanol into electricity using catalytic electrodes. But making single layers of densely packed enzymes, the functional part of such catalytic electrodes, has been a challenge. This new research shows that precisely engineered gold nanoparticles can be used to "glue" enzymes together to form oriented and ordered single layers, and that these monolayers are mechanically stable enough to be transferred onto a solid surface such as an electrode.

For this research, the scientists attached gold nanoparticles to an enzyme complex that helps drug-resistant tuberculosis bacteria survive, which has been studied by Brookhaven Lab biologist Huilin Li. The researcher
'"/>

Contact: Karen McNulty Walsh
kmcnulty@bnl.gov
631-344-8350
DOE/Brookhaven National Laboratory
27-Jun-2007


Page: 1 2 3

Related biology news :

1. Gold nanoparticles may pan out as tool for cancer diagnosis
2. Under magnetic force, nanoparticles may deliver gene therapy
3. UCSB researchers show how to make polymeric micro- and nanoparticles
4. In nature, proteins sweep up nanoparticles
5. Bacteria ferry nanoparticles into cells for early diagnosis, treatment
6. MU researchers examine the environmental effects of silver nanoparticles
7. Work with nanoparticles may lead to on-the-spot virus detector
8. Widely used iron nanoparticles exhibit toxic effects on neuronal cells
9. Test finds manufactured nanoparticles dont harm soil ecology
10. DNA nanoparticles hold promise in gene therapy for Parkinsons disease
11. MIT develops nanoparticles to battle cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pairing nanoparticles with proteins

(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... 2015 Veolia’s environmental monitoring technology ... American distribution agreement with VWR to distribute TECTA™ ... more than 160 years of experience, VWR, a ... laboratory and production facilities, has cultivated a value ... services to enable science. Endetec’s TECTA™ B16, ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 This ... history, especially for lawns. US Patented Pearl’s Premium ... for lawns around the country that are coming out ... that addresses a number of major global concerns related ... the “non-grass” grass – the alternative to the standard, ...
(Date:5/20/2015)... -- Health eCareers, the healthcare industry,s online career hub, ... looking for the flexibility of short-term assignments through ... tool dedicated exclusively to temporary and shift work ... employers to quickly find and hire experienced professionals ... other temporary positions, eliminating the time and resources ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
Cached News: